000			02053 a2200565 4500
005			20250514184611.0
264		0	_c20041025
008			200410s 0 0 eng d
022			_a0959-4973
024	7		_a10.1097/00001813-200401000-00003 _2doi
040			_aNLM _beng _cNLM
100	1		_aMross, Klaus
245	0	0	_aPhase I clinical and pharmacokinetic study of BBR 3576, a novel aza-anthrapyrazole, administered i.v. every 4 weeks in patients with advanced solid tumors: a phase I study group trial of the Central European Society of Anticancer-Drug Research (CESAR). _h[electronic resource]
260			_bAnti-cancer drugs _cJan 2004
300			_a15-22 p. _bdigital
500			_aPublication Type: Clinical Trial; Clinical Trial, Phase I; Journal Article
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAnthracyclines _xadministration & dosage
650	0	4	_aAntineoplastic Agents _xadministration & dosage
650	0	4	_aArea Under Curve
650	0	4	_aDrug Administration Schedule
650	0	4	_aFemale
650	0	4	_aHalf-Life
650	0	4	_aHeterocyclic Compounds, 4 or More Rings _xadministration & dosage
650	0	4	_aHumans
650	0	4	_aInfusion Pumps
650	0	4	_aLeukopenia _xchemically induced
650	0	4	_aMale
650	0	4	_aMaximum Tolerated Dose
650	0	4	_aMiddle Aged
650	0	4	_aMolecular Structure
650	0	4	_aNeoplasms _xblood
650	0	4	_aNeutropenia _xchemically induced
650	0	4	_aPyrazoles _xadministration & dosage
650	0	4	_aStomatitis _xchemically induced
700	1		_aScheulen, Max E
700	1		_aLicht, Thomas
700	1		_aUnger, Clemens
700	1		_aRichly, Heike
700	1		_aStern, Angelika C
700	1		_aKutz, Klaus
700	1		_aCamboni, Maria G
700	1		_aBarbieri, Paola
700	1		_aVerdi, Elena
700	1		_aVincenzi, Beatrice
700	1		_aBernareggi, Alberto
773	0		_tAnti-cancer drugs _gvol. 15 _gno. 1 _gp. 15-22
856	4	0	_uhttps://doi.org/10.1097/00001813-200401000-00003 _zAvailable from publisher's website
999			_c14803764 _d14803764